Thursday, 5 November 2026European Markets
ExploreSearch
ViaNews EU
stockMarket

DISRUPTIVE CAP SHA Stock Over 21% Down In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of DISRUPTIVE CAP SHA (AEX-Index: DCACS.AS) dropped by a staggering 21.28% in 10 sessions from €9.4 to €7.40 at 10:09 EST on Thursday, after five sequential sessions in a row of losses. AEX-Index is falling 0.32% to €739.41, after three consecutive sessions in a row of gains.

About DISRUPTIVE CAP SHA

Disruptive Capital Acquisition Company Limited does not have significant operations. It intends to complete a merger, amalgamation, share exchange, asset and/or liability acquisition, share purchase, reorganization, or related business combination with a target business or entity operating in the financial services sector. The company was incorporated in 2021 and is based in Saint Peter Port, Guernsey.

Volume

Today's last reported volume for DISRUPTIVE CAP SHA is 243 which is 80.8% below its average volume of 745.

More news about DISRUPTIVE CAP SHA (DCACS.AS).

Categories

stockMarket

Tags

Stock PricePrice DownMarket Session NowDCACS.ASStock Price DownStock Market NowMarket SessionStock MarketStockDISRUPTIVE CAP SHA
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com